Search
Norfloxacin
go.drugbank.com/drugs/DB01059ApprovedInvestigationalA synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.
Products: NORMED 400 - U, N-FLOXA 200Ethylhexyl methoxycrylene
go.drugbank.com/drugs/DB11226ApprovedEthylhexyl methoxycrylene is a photostabilizer that preserves the effectiveness of UV filters by interacting with both the singlet and triplet states [F104]. … It returns UV filters to their ground states without absorbing sunlight [F104].
Fosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalGenerally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting … Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies [A32865].
Ethchlorvynol
go.drugbank.com/drugs/DB00189ApprovedIllicitWithdrawnIt has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.
Prasterone
go.drugbank.com/drugs/DB01708ApprovedInvestigationalNutraceuticalIn Canada, a prescription is required to buy DHEA. … Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary.
Moxidectin
go.drugbank.com/drugs/DB11431ApprovedInvestigationalVet approvedMoxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side chain at carbon 25 and a unique methoxime moiety at carbon 23. … [A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June 13, 2018.[L2970]
Mixtures: Advocate Spot-on Solution for Small Dogs, Advocate Spot-on Solution for Large DogsOndansetron
go.drugbank.com/drugs/DB00904ApprovedInvestigationalWithdrawnHaving been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy. … It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Nu-ondansetron, ONDANEErgoloid mesylate
go.drugbank.com/drugs/DB01049Approved[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … [L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA.
Synonyms: co-dergocrine mesilate, co-dergocrine mesylateCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCalcium carbimide
go.drugbank.com/drugs/DB09116ApprovedWithdrawnIts effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic product acetaldehyde. … Calcium carbimide was conceived as an alternative for the treatment of alcoholism with a reduced side effect profile either when it is consumed accompanied by alcohol or without it.
Cefdinir
go.drugbank.com/drugs/DB00535ApprovedInvestigationalCefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. … [A180739] Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.[A180724,A180727]
International brands: Xi Fu Ni